These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33954893)

  • 1. Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.
    Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Shawky AM; Mekhemer GAH; Alrumaihi F; Moustafa MF; Atia MAM
    Cell Biochem Biophys; 2021 Jun; 79(2):189-200. PubMed ID: 33954893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
    Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Mekhemer GAH; Shawky AM; Moustafa MF; Atia MAM
    Mol Inform; 2022 Feb; 41(2):e2060039. PubMed ID: 34491628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study.
    Ibrahim MAA; Abdelrahman AHM; Badr EAA; Almansour NM; Alzahrani OR; Ahmed MN; Soliman MES; Naeem MA; Shawky AM; Sidhom PA; Mekhemer GAH; Atia MAM
    Mol Divers; 2022 Dec; 26(6):3255-3277. PubMed ID: 35224675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an
    Ibrahim MAA; Abdeljawaad KAA; Jaragh-Alhadad LA; Oraby HF; Atia MAM; Alzahrani OR; Mekhemer GAH; Moustafa MF; Shawky AM; Sidhom PA; Abdelrahman AHM
    J Biomol Struct Dyn; 2023; 41(23):13977-13992. PubMed ID: 36883864
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Almansour NM; Abdelrahman AHM; Ismail Fagiree E; Ibrahim MAA
    J Biomol Struct Dyn; 2023; 41(16):7651-7664. PubMed ID: 36120948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2).
    Zattoni IF; Kronenberger T; Kita DH; Guanaes LD; Guimarães MM; de Oliveira Prado L; Ziasch M; Vesga LC; Gomes de Moraes Rego F; Picheth G; Gonçalves MB; Noseda MD; Ducatti DRB; Poso A; Robey RW; Ambudkar SV; Moure VR; Gonçalves AG; Valdameri G
    Chem Biol Interact; 2022 Jan; 351():109718. PubMed ID: 34717915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
    Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
    Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
    Vesga LC; Kronenberger T; Tonduru AK; Kita DH; Zattoni IF; Bernal CC; Bohórquez ARR; Mendez-Sánchez SC; Ambudkar SV; Valdameri G; Poso A
    ChemMedChem; 2021 Sep; 16(17):2686-2694. PubMed ID: 33844464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
    Wu ZX; Yang Y; Wang G; Wang JQ; Teng QX; Sun L; Lei ZN; Lin L; Chen ZS; Zou C
    Cancer Sci; 2020 Aug; 111(8):2872-2882. PubMed ID: 32478948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
    Narayanan S; Wu ZX; Wang JQ; Ma H; Acharekar N; Koya J; Yoganathan S; Fang S; Chen ZS; Pan Y
    Int J Biol Sci; 2021; 17(10):2652-2665. PubMed ID: 34326700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.
    Wu CP; Hsiao SH; Murakami M; Lu MJ; Li YQ; Hsieh CH; Ambudkar SV; Wu YS
    Cancer Lett; 2017 Nov; 409():56-65. PubMed ID: 28893612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
    Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
    Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    Zattoni IF; Delabio LC; Dutra JP; Kita DH; Scheiffer G; Hembecker M; Pereira GDS; Moure VR; Valdameri G
    Eur J Med Chem; 2022 Jul; 237():114346. PubMed ID: 35483322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
    Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
    Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.